Nuvectis Pharma Inc. (NVCT)
Nuvectis Pharma Inc. (NVCT) Stock Price, Analysis & Data
| Bid | 14.13 |
| Market Cap | 636.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.27M |
| Beta | -0.26 |
| EPS (ttm) | -1.33 |
| PE Ratio (ttm) | n/a |
| Forward PE | -20.35 |
| P/B (ttm) | 57.47 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 3, 2026 |
| Ask | 24.99 |
| Volume | 78,603 |
| Avg. Volume (20D) | 309,032 |
| Open | 19.68 |
| Previous Close | 19.41 |
| Day's Range | 19.37 - 19.74 |
| 52-Week Range | 5.55 - 29.27 |
| Analyst | Strong Buy |
| Price Target | 34 (74.00%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NVCT
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its na...
Financial Performance
In 2025, Nuvectis Pharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -26.44M, an increase of 39.17%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for NVCT stock is "Strong Buy". The 12-month stock price forecast is 34, which is upside of 74% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
